Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.

Journal	International journal of environmental research and public health
Study Type	Clinical Study
Population	Human participants

This study provides real-world evidence on how different cannabis formulations affect anxiety in motivated users over time. Understanding product-specific anxiolytic effects is crucial for clinical decision-making when patients request cannabis for anxiety management.

This longitudinal observational study tracked adults using cannabis therapeutically for anxiety over 30 days, comparing flower versus edible products. The research builds on established cannabinoid pharmacology showing THC’s anxiogenic potential versus CBD’s anxiolytic properties. Daily self-reporting revealed differential anxiety reduction patterns between delivery methods, though the study appears incomplete in the available abstract. Limitations likely include self-selection bias and lack of standardized dosing or cannabinoid ratios.

“I see patients struggling with this exact question daily – which cannabis product might help versus harm their anxiety. Real-world data on product-specific outcomes helps bridge the gap between cannabinoid science and clinical reality.”

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it:

{“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41752306/”, “about”: “international journal environmental research public health”, “isPartOf”: “International journal of environmental research and public health”}